Search

for
Search:

GlossaryIncretin Mimetics (incretin-based therapies)

mimic gut hormones to enhance insulin release in diabetes

Incretin mimetics are a class of medications used to treat type 2 diabetes by mimicking the action of incretin hormones, which stimulate insulin release in response to meals. These drugs help lower blood sugar levels by enhancing insulin secretion, slowing gastric emptying, and reducing appetite.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 47 results

A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome

research A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome

61 citations, January 2015 in “Hormones”

Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.

research Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS

2 citations, December 2022 in “Journal of Clinical Medicine”

Medications for glucose metabolism and weight control, combined therapy options, and herbal medicines may help regulate menstrual cycle in adolescents with PCOS.

research The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome

July 2023 in “Journal of Clinical Medicine”

Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.

research Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing

68 citations, January 2022 in “International Journal of Molecular Sciences”

PCOS management includes lifestyle changes and medications, with ongoing research into repurposed drugs for better treatment options.

research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

59 citations, August 2021 in “Frontiers in Endocrinology”

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

View more "incretin-based therapies" in research →

Community Join

0 / 0 results

— no results